drugset / Trial / NCT01870986
Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
RandomizedParallel-groupTriple-blindBasic science
Summary
This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | PF-06410293 | Protein / enzyme biologic | 40 mg | Subcutaneous |
Indications
No indication recorded.